Malaria Research Today is a free monthly online journal that collates and summarizes the latest research about Malaria, including details on prevention, treatment, causes, mosquitoes.

Volume 4 (2007), Issue 5 (May)

1. New concepts in vaccine development in malaria.
   Curr Opin Infect Dis, 20(3): 311-6. [Abstract] [Full-text]
2. Iron deficiency influences the course of malaria in Plasmodium berghei infected mice.
   Biochem Biophys Res Commun, 357(3): 608-14. [Abstract] [Full-text]
3. Impact of competitive inhibition and sequence variation upon the sensitivity of malaria PCR.
   J Clin Microbiol, 45(5): 1621-3. [Abstract] [Full-text]
4. Amodiaquine failure associated with erythrocytic glutathione in Plasmodium falciparum malaria.
   Malar J, 6: 47. [Abstract] [Full-text]
5. A rational strategy for a malarial vaccine development.
   Microbes Infect, 9(6): 751-60. [Abstract] [Full-text]
6. Rational approaches to developing an anti-disease vaccine against malaria.
   Microbes Infect, 9(6): 784-91. [Abstract] [Full-text]
7. Malaria transmission-blocking vaccines: the bonus of effective malaria control.
   Microbes Infect, 9(6): 792-5. [Abstract] [Full-text]
8. Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine.
   Microbes Infect, 9(6): 761-6. [Abstract] [Full-text]
9. Development of vaccines against Plasmodium falciparum malaria: taking lessons from naturally acquired protective immunity.
   Microbes Infect, 9(6): 772-6. [Abstract] [Full-text]
10. Peptide based malaria vaccine development: personal considerations.
    Microbes Infect, 9(6): 767-71. [Abstract] [Full-text]
11. CTLA-4 blockade differentially influences the outcome of non-lethal and lethal Plasmodium yoelii infections.
    Microbes Infect, 9(6): 687-94. [Abstract] [Full-text]
12. The naturally acquired immunity in severe malaria and its implication for a PfEMP-1 based vaccine.
    Microbes Infect, 9(6): 777-83. [Abstract] [Full-text]
13. Magnetic resonance spectroscopy reveals an impaired brain metabolic profile in mice resistant to cerebral malaria infected with Plasmodium berghei ANKA.
    J Biol Chem, 282(19): 14505-14. [Abstract] [Full-text]
14. Genetic polymorphisms influence Plasmodium ovale PCR detection accuracy.
    J Clin Microbiol, 45(5): 1624-7. [Abstract] [Full-text]
15. Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
    Vaccine, 25(22): 4487-501. [Abstract] [Full-text]
16. Treatment-seeking behaviour for febrile illness in an area of seasonal malaria transmission in rural Ethiopia.
    Malar J, 6: 49. [Abstract] [Full-text]
17. IL-12 producing monocytes and IFN-gamma and TNF-alpha producing T-lymphocytes are increased in placentas infected by Plasmodium falciparum.
    J Reprod Immunol, 74(1): 152-62. [Abstract] [Full-text]
18. Malaria-infected mice are cured by a single dose of novel artemisinin derivatives.
    J Med Chem, 50(10): 2516-9. [Abstract] [Full-text]
19. Antimalarial drug prescribing practice in private and public health facilities in South-east Nigeria: a descriptive study.
    Malar J, 6: 55. [Abstract] [Full-text]
20. Outcome of life-threatening malaria in African children requiring endotracheal intubation.
    Malar J, 6: 51. [Abstract] [Full-text]
21. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré.
    Malar J, 6: 54. [Abstract] [Full-text]
22. Congenital malaria, an important differential diagnosis to consider when evaluating febrile infants of immigrant mothers.
    Pediatr Emerg Care, 23(5): 326-9. [Abstract] [Full-text]
23. Malaria vector control by indoor residual insecticide spraying on the tropical island of Bioko, Equatorial Guinea.
    Malar J, 6: 52. [Abstract] [Full-text]
24. An exploratory study of community factors relevant for participatory malaria control on Rusinga Island, western Kenya.
    Malar J, 6: 48. [Abstract] [Full-text]
25. Use of over-the-counter malaria medicines in children and adults in three districts in Kenya: implications for private medicine retailer interventions.
    Malar J, 6: 57. [Abstract] [Full-text]
26. Treatment of malaria in the United States: a systematic review.
    JAMA, 297(20): 2264-77. [Abstract] [Full-text]
27. Controversies and misconceptions in malaria chemoprophylaxis for travelers.
    JAMA, 297(20): 2251-63. [Abstract] [Full-text]
28. Estimating the number of insecticide-treated nets required by African households to reach continent-wide malaria coverage targets.
    JAMA, 297(20): 2241-50. [Abstract] [Full-text]
29. Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children.
    JAMA, 297(20): 2232-40. [Abstract] [Full-text]
30. Improved diagnostic testing and malaria treatment practices in Zambia.
    JAMA, 297(20): 2227-31. [Abstract] [Full-text]
31. Hemoglobin variants and disease manifestations in severe falciparum malaria.
    JAMA, 297(20): 2220-6. [Abstract] [Full-text]
32. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.
    JAMA, 297(20): 2210-9. [Abstract] [Full-text]
33. Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial.
    JAMA, 297(20): 2201-9. [Abstract] [Full-text]
34. A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian adults.
    Parasite Immunol, 29(6): 309-17. [Abstract] [Full-text]
35. Measures of clinical malaria in field trials of interventions against Plasmodium falciparum.
    Malar J, 6: 53. [Abstract] [Full-text]
36. Transcriptional analysis of an immune-responsive serine protease from Indian malarial vector, Anopheles culicifacies.
    BMC Mol Biol, 8: 33. [Abstract] [Full-text]
37. Global Fund grant programmes: an analysis of evaluation scores.
    Lancet, 369(9575): 1807-13. [Abstract] [Full-text]
38. The importance of human FcgammaRI in mediating protection to malaria.
    PLoS Pathog, 3(5): e72. [Abstract] [Full-text]
39. HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites.
    PLoS Med, 4(5): e181. [Abstract] [Full-text]
40. A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa.
    J Infect Dis, 196(1): 165-72. [Abstract] [Full-text]
41. Effects of sex, parity, and sequence variation on seroreactivity to candidate pregnancy malaria vaccine antigens.
    J Infect Dis, 196(1): 155-64. [Abstract] [Full-text]
42. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update.
    J Infect Dis, 196(1): 145-54. [Abstract] [Full-text]
43. Children in Burkina Faso who are protected by insecticide-treated materials are able to clear drug-resistant parasites better than unprotected children.
    J Infect Dis, 196(1): 138-44. [Abstract] [Full-text]
44. CD16+ monocyte subset preferentially harbors HIV-1 and is expanded in pregnant malawian women with plasmodium falciparum malaria and HIV-1 infection.
    J Infect Dis, 196(1): 38-42. [Abstract] [Full-text]
45. HIV, malaria, and infant anemia as risk factors for postneonatal infant mortality among HIV-seropositive women in Kisumu, Kenya.
    J Infect Dis, 196(1): 30-7. [Abstract] [Full-text]

© 2004-2008 Malaria Research Today. All Rights Reserved.